Cell and Gene Therapy Market Size, Share, Demand

Table Of Content

Executive Summary

Research Scope & Segmentation

Research Objectives
Limitations & Assumptions
Market Scope & Segmentation
Currency & Pricing Considered

Market Opportunity Assessment

Emerging Regions / Countries
Emerging Companies
Emerging Applications / End Use

Market Trends

Drivers
Market Warning Factors
Latest Macro Economic Indicators
Geopolitical Impact
Technology Factors

Market Assessment

Porters Five Forces Analysis
Value Chain Analysis

Regulatory Framework

North America
Europe
APAC
Middle East and Africa
LATAM

ESG Trends

Global Cell and Gene Therapy Market Size Analysis

Global Cell and Gene Therapy Market Introduction
By Therapy Type
1. Introduction
  1. Therapy Type By Value
2. Cell Therapy
  1. By Value
  2. CAR-T
    1. CAR-T By Value
    2. Autologous CAR-T
      1. Autologous CAR-T By Value
    3. Allogeneic CAR-T
      1. Allogeneic CAR-T By Value
  3. CAR-NK
    1. CAR-NK By Value
  4. B-Cell
    1. B-Cell By Value
  5. Other
    1. Other By Value
3. Gene Therapy
  1. By Value
  2. Viral
    1. Viral By Value
    2. AAV
      1. AAV By Value
    3. Lentiviral vectors
      1. Lentiviral vectors By Value
    4. Others
      1. Others By Value
  3. Non-viral
    1. Non-viral By Value
By Application
1. Introduction
  1. Application By Value
2. Oncology
  1. By Value
3. Dermatology
  1. By Value
4. Musculoskeletal
  1. By Value
5. Others
  1. By Value
By Manufacturers
1. Introduction
  1. Manufacturers By Value
2. Biopharmaceutical and biotechnology companies
  1. By Value
3. Pharmaceutical companies
  1. By Value
4. CDMOs/CMOs
  1. By Value
5. Others
  1. By Value

North America Market Analysis

Introduction
By Therapy Type
1. Introduction
  1. Therapy Type By Value
2. Cell Therapy
  1. By Value
  2. CAR-T
    1. CAR-T By Value
    2. Autologous CAR-T
      1. Autologous CAR-T By Value
    3. Allogeneic CAR-T
      1. Allogeneic CAR-T By Value
  3. CAR-NK
    1. CAR-NK By Value
  4. B-Cell
    1. B-Cell By Value
  5. Other
    1. Other By Value
3. Gene Therapy
  1. By Value
  2. Viral
    1. Viral By Value
    2. AAV
      1. AAV By Value
    3. Lentiviral vectors
      1. Lentiviral vectors By Value
    4. Others
      1. Others By Value
  3. Non-viral
    1. Non-viral By Value
By Application
1. Introduction
  1. Application By Value
2. Oncology
  1. By Value
3. Dermatology
  1. By Value
4. Musculoskeletal
  1. By Value
5. Others
  1. By Value
By Manufacturers
1. Introduction
  1. Manufacturers By Value
2. Biopharmaceutical and biotechnology companies
  1. By Value
3. Pharmaceutical companies
  1. By Value
4. CDMOs/CMOs
  1. By Value
5. Others
  1. By Value
U.S.
1. By Therapy Type
  1. Introduction
    1. Therapy Type By Value
  2. Cell Therapy
    1. By Value
    2. CAR-T
      1. CAR-T By Value
      2. Autologous CAR-T
        
        Autologous CAR-T By Value
      3. Allogeneic CAR-T
        
        Allogeneic CAR-T By Value
    3. CAR-NK
      1. CAR-NK By Value
    4. B-Cell
      1. B-Cell By Value
    5. Other
      1. Other By Value
  3. Gene Therapy
    1. By Value
    2. Viral
      1. Viral By Value
      2. AAV
        
        AAV By Value
      3. Lentiviral vectors
        
        Lentiviral vectors By Value
      4. Others
        
        Others By Value
    3. Non-viral
      1. Non-viral By Value
2. By Application
  1. Introduction
    1. Application By Value
  2. Oncology
    1. By Value
  3. Dermatology
    1. By Value
  4. Musculoskeletal
    1. By Value
  5. Others
    1. By Value
3. By Manufacturers
  1. Introduction
    1. Manufacturers By Value
  2. Biopharmaceutical and biotechnology companies
    1. By Value
  3. Pharmaceutical companies
    1. By Value
  4. CDMOs/CMOs
    1. By Value
  5. Others
    1. By Value
Canada

Europe Market Analysis

Introduction
By Therapy Type
1. Introduction
  1. Therapy Type By Value
2. Cell Therapy
  1. By Value
  2. CAR-T
    1. CAR-T By Value
    2. Autologous CAR-T
      1. Autologous CAR-T By Value
    3. Allogeneic CAR-T
      1. Allogeneic CAR-T By Value
  3. CAR-NK
    1. CAR-NK By Value
  4. B-Cell
    1. B-Cell By Value
  5. Other
    1. Other By Value
3. Gene Therapy
  1. By Value
  2. Viral
    1. Viral By Value
    2. AAV
      1. AAV By Value
    3. Lentiviral vectors
      1. Lentiviral vectors By Value
    4. Others
      1. Others By Value
  3. Non-viral
    1. Non-viral By Value
By Application
1. Introduction
  1. Application By Value
2. Oncology
  1. By Value
3. Dermatology
  1. By Value
4. Musculoskeletal
  1. By Value
5. Others
  1. By Value
By Manufacturers
1. Introduction
  1. Manufacturers By Value
2. Biopharmaceutical and biotechnology companies
  1. By Value
3. Pharmaceutical companies
  1. By Value
4. CDMOs/CMOs
  1. By Value
5. Others
  1. By Value
U.K.
1. By Therapy Type
  1. Introduction
    1. Therapy Type By Value
  2. Cell Therapy
    1. By Value
    2. CAR-T
      1. CAR-T By Value
      2. Autologous CAR-T
        
        Autologous CAR-T By Value
      3. Allogeneic CAR-T
        
        Allogeneic CAR-T By Value
    3. CAR-NK
      1. CAR-NK By Value
    4. B-Cell
      1. B-Cell By Value
    5. Other
      1. Other By Value
  3. Gene Therapy
    1. By Value
    2. Viral
      1. Viral By Value
      2. AAV
        
        AAV By Value
      3. Lentiviral vectors
        
        Lentiviral vectors By Value
      4. Others
        
        Others By Value
    3. Non-viral
      1. Non-viral By Value
2. By Application
  1. Introduction
    1. Application By Value
  2. Oncology
    1. By Value
  3. Dermatology
    1. By Value
  4. Musculoskeletal
    1. By Value
  5. Others
    1. By Value
3. By Manufacturers
  1. Introduction
    1. Manufacturers By Value
  2. Biopharmaceutical and biotechnology companies
    1. By Value
  3. Pharmaceutical companies
    1. By Value
  4. CDMOs/CMOs
    1. By Value
  5. Others
    1. By Value
Germany
France
Spain
Italy
Russia
Nordic
Benelux
Rest of Europe

APAC Market Analysis

Introduction
By Therapy Type
1. Introduction
  1. Therapy Type By Value
2. Cell Therapy
  1. By Value
  2. CAR-T
    1. CAR-T By Value
    2. Autologous CAR-T
      1. Autologous CAR-T By Value
    3. Allogeneic CAR-T
      1. Allogeneic CAR-T By Value
  3. CAR-NK
    1. CAR-NK By Value
  4. B-Cell
    1. B-Cell By Value
  5. Other
    1. Other By Value
3. Gene Therapy
  1. By Value
  2. Viral
    1. Viral By Value
    2. AAV
      1. AAV By Value
    3. Lentiviral vectors
      1. Lentiviral vectors By Value
    4. Others
      1. Others By Value
  3. Non-viral
    1. Non-viral By Value
By Application
1. Introduction
  1. Application By Value
2. Oncology
  1. By Value
3. Dermatology
  1. By Value
4. Musculoskeletal
  1. By Value
5. Others
  1. By Value
By Manufacturers
1. Introduction
  1. Manufacturers By Value
2. Biopharmaceutical and biotechnology companies
  1. By Value
3. Pharmaceutical companies
  1. By Value
4. CDMOs/CMOs
  1. By Value
5. Others
  1. By Value
China
1. By Therapy Type
  1. Introduction
    1. Therapy Type By Value
  2. Cell Therapy
    1. By Value
    2. CAR-T
      1. CAR-T By Value
      2. Autologous CAR-T
        
        Autologous CAR-T By Value
      3. Allogeneic CAR-T
        
        Allogeneic CAR-T By Value
    3. CAR-NK
      1. CAR-NK By Value
    4. B-Cell
      1. B-Cell By Value
    5. Other
      1. Other By Value
  3. Gene Therapy
    1. By Value
    2. Viral
      1. Viral By Value
      2. AAV
        
        AAV By Value
      3. Lentiviral vectors
        
        Lentiviral vectors By Value
      4. Others
        
        Others By Value
    3. Non-viral
      1. Non-viral By Value
2. By Application
  1. Introduction
    1. Application By Value
  2. Oncology
    1. By Value
  3. Dermatology
    1. By Value
  4. Musculoskeletal
    1. By Value
  5. Others
    1. By Value
3. By Manufacturers
  1. Introduction
    1. Manufacturers By Value
  2. Biopharmaceutical and biotechnology companies
    1. By Value
  3. Pharmaceutical companies
    1. By Value
  4. CDMOs/CMOs
    1. By Value
  5. Others
    1. By Value
Korea
Japan
India
Australia
Taiwan
South East Asia
Rest of Asia-Pacific

Middle East and Africa Market Analysis

Introduction
By Therapy Type
1. Introduction
  1. Therapy Type By Value
2. Cell Therapy
  1. By Value
  2. CAR-T
    1. CAR-T By Value
    2. Autologous CAR-T
      1. Autologous CAR-T By Value
    3. Allogeneic CAR-T
      1. Allogeneic CAR-T By Value
  3. CAR-NK
    1. CAR-NK By Value
  4. B-Cell
    1. B-Cell By Value
  5. Other
    1. Other By Value
3. Gene Therapy
  1. By Value
  2. Viral
    1. Viral By Value
    2. AAV
      1. AAV By Value
    3. Lentiviral vectors
      1. Lentiviral vectors By Value
    4. Others
      1. Others By Value
  3. Non-viral
    1. Non-viral By Value
By Application
1. Introduction
  1. Application By Value
2. Oncology
  1. By Value
3. Dermatology
  1. By Value
4. Musculoskeletal
  1. By Value
5. Others
  1. By Value
By Manufacturers
1. Introduction
  1. Manufacturers By Value
2. Biopharmaceutical and biotechnology companies
  1. By Value
3. Pharmaceutical companies
  1. By Value
4. CDMOs/CMOs
  1. By Value
5. Others
  1. By Value
UAE
1. By Therapy Type
  1. Introduction
    1. Therapy Type By Value
  2. Cell Therapy
    1. By Value
    2. CAR-T
      1. CAR-T By Value
      2. Autologous CAR-T
        
        Autologous CAR-T By Value
      3. Allogeneic CAR-T
        
        Allogeneic CAR-T By Value
    3. CAR-NK
      1. CAR-NK By Value
    4. B-Cell
      1. B-Cell By Value
    5. Other
      1. Other By Value
  3. Gene Therapy
    1. By Value
    2. Viral
      1. Viral By Value
      2. AAV
        
        AAV By Value
      3. Lentiviral vectors
        
        Lentiviral vectors By Value
      4. Others
        
        Others By Value
    3. Non-viral
      1. Non-viral By Value
2. By Application
  1. Introduction
    1. Application By Value
  2. Oncology
    1. By Value
  3. Dermatology
    1. By Value
  4. Musculoskeletal
    1. By Value
  5. Others
    1. By Value
3. By Manufacturers
  1. Introduction
    1. Manufacturers By Value
  2. Biopharmaceutical and biotechnology companies
    1. By Value
  3. Pharmaceutical companies
    1. By Value
  4. CDMOs/CMOs
    1. By Value
  5. Others
    1. By Value
Turkey
Saudi Arabia
South Africa
Egypt
Nigeria
Rest of MEA

LATAM Market Analysis

Introduction
By Therapy Type
1. Introduction
  1. Therapy Type By Value
2. Cell Therapy
  1. By Value
  2. CAR-T
    1. CAR-T By Value
    2. Autologous CAR-T
      1. Autologous CAR-T By Value
    3. Allogeneic CAR-T
      1. Allogeneic CAR-T By Value
  3. CAR-NK
    1. CAR-NK By Value
  4. B-Cell
    1. B-Cell By Value
  5. Other
    1. Other By Value
3. Gene Therapy
  1. By Value
  2. Viral
    1. Viral By Value
    2. AAV
      1. AAV By Value
    3. Lentiviral vectors
      1. Lentiviral vectors By Value
    4. Others
      1. Others By Value
  3. Non-viral
    1. Non-viral By Value
By Application
1. Introduction
  1. Application By Value
2. Oncology
  1. By Value
3. Dermatology
  1. By Value
4. Musculoskeletal
  1. By Value
5. Others
  1. By Value
By Manufacturers
1. Introduction
  1. Manufacturers By Value
2. Biopharmaceutical and biotechnology companies
  1. By Value
3. Pharmaceutical companies
  1. By Value
4. CDMOs/CMOs
  1. By Value
5. Others
  1. By Value
Brazil
1. By Therapy Type
  1. Introduction
    1. Therapy Type By Value
  2. Cell Therapy
    1. By Value
    2. CAR-T
      1. CAR-T By Value
      2. Autologous CAR-T
        
        Autologous CAR-T By Value
      3. Allogeneic CAR-T
        
        Allogeneic CAR-T By Value
    3. CAR-NK
      1. CAR-NK By Value
    4. B-Cell
      1. B-Cell By Value
    5. Other
      1. Other By Value
  3. Gene Therapy
    1. By Value
    2. Viral
      1. Viral By Value
      2. AAV
        
        AAV By Value
      3. Lentiviral vectors
        
        Lentiviral vectors By Value
      4. Others
        
        Others By Value
    3. Non-viral
      1. Non-viral By Value
2. By Application
  1. Introduction
    1. Application By Value
  2. Oncology
    1. By Value
  3. Dermatology
    1. By Value
  4. Musculoskeletal
    1. By Value
  5. Others
    1. By Value
3. By Manufacturers
  1. Introduction
    1. Manufacturers By Value
  2. Biopharmaceutical and biotechnology companies
    1. By Value
  3. Pharmaceutical companies
    1. By Value
  4. CDMOs/CMOs
    1. By Value
  5. Others
    1. By Value
Mexico
Argentina
Chile
Colombia
Rest of LATAM

Competitive Landscape

Cell and Gene Therapy Market Share By Players
M&A Agreements & Collaboration Analysis

Market Players Assessment

Novartis AG
1. Overview
2. Business Information
3. Revenue
4. ASP
5. SWOT Analysis
6. Recent Developments
Amgen Inc.
Vericel Corporation
Gilead Sciences, Inc.
Bluebird Bio, Inc.
Bristol-Myers Squibb Company
Biomarin
Johnson & Johnson and its affiliates
uniQure NV.
Celgene Corporation
ImmunoACT
Cellectis
Astellas Pharma Inc.
Atara Biotherapeutics, Inc.
Orchard Therapeutics plc
Sana Biotechnology
Bayer AG
Hoffmann-La Roche Ltd
Krystal Biotech, Inc
ALLOGENE THERAPEUTICS

Research Methodology

Research Data
1. Secondary Data
  1. Major secondary sources
  2. Key data from secondary sources
2. Primary Data
  1. Key data from primary sources
  2. Breakdown of primaries
3. Secondary And Primary Research
  1. Key industry insights
Market Size Estimation
1. Bottom-Up Approach
2. Top-Down Approach
3. Market Projection
Research Assumptions
1. Assumptions
Limitations
Risk Assessment